The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Hepatic Failure and Lactic Acidosis Due to Fialuridine (FIAU), an Investigational Nucleoside Analogue for Chronic Hepatitis B
Open accessAbstract
BACKGROUND: We describe severe and unexpected multisystem toxicity that occurred during a study of the antiviral nucleoside analogue fialuridine (1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodouracil, or FIAU) as therapy for chronic hepatitis B virus infection. METHODS: Fifteen patients with chronic hepatitis B were randomly assigned to receive fialuridine at a dose of either 0.10 or 0.25 mg per kilogram of body weight per day for 24 weeks and were monitored every 1 to 2 weeks by means of a physical examination, blood tests, and testing for hepatitis B virus markers. RESULTS: During the 13th week lactic acidosis and liver failure suddenly developed in one patient. The study was terminated on an emergency basis, and all treatment with fialuridine was discontinued. Seven patients were found to have severe hepatotoxicity, with progressive lactic acidosis, worsening jaundice, and deteriorating hepatic synthetic function despite the discontinuation of fialuridine. Three other patients had mild hepatotoxicity. Several patients also had pancreatitis, neuropathy, or myopathy. Of the seven patients with severe hepatotoxicity, five died and two survived after liver transplantation. Histologic analysis of liver tissue revealed marked accumulation of microvesicular and macrovesicular fat, with minimal necrosis of hepatocytes or architectural changes. Electron microscopy showed abnormal mitochondria and the accumulation of fat in hepatocytes. CONCLUSIONS: In patients with chronic hepatitis B, treatment with fialuridine induced a severe toxic reaction characterized by hepatic failure, lactic acidosis, pancreatitis, neuropathy, and myopathy. This toxic reaction was probably caused by widespread mitochondrial damage and may occur infrequently with other nucleoside analogues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fialuridine (Section 7.1) and troglitazone (Section 7.4) are intrinsic toxicodynamic failures, driven by human-relevant mitochondrial injury and reactive-metabolite formation, respectively.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fialuridine, an antiviral nucleoside analogue, caused catastrophic hepatic failure and lactic acidosis in a 1993 clinical trial, resulting in five deaths and two liver transplantations.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies across multiple species showed no indication of the severe mitochondrial toxicity observed in humans, because fialuridine’s incorporation into mitochondrial DNA is mediated by a human-specific mitochondrial transporter [69,70].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fourth, idiosyncratic toxicities, such as those underlying the fialuridine and troglitazone failures, are by definition not captured by any pharmacokinetic scaling framework, and even sophisticated PBPK or PBPK–PD models cannot reliably anticipate them without orthogonal mechanistic assays [69,70,75,76].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“even sophisticated PBPK or PBPK–PD models cannot reliably anticipate them without orthogonal mechanistic assays [69,70,75,76]”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [69]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Even a pilot study on 43 patients treated for 2 and 4 weeks duration with Fialuridine did not reveal any signs of hepatic toxicity on initial examination.[17]”
From TGN1412: From Discovery to Disaster (2010) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“During 13th week of phase II studies, one of the patients suddenly developed hepatic toxicity and lactic acidosis. At this point, trial was stopped for all other patients.”
From TGN1412: From Discovery to Disaster (2010) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“Even after discontinuation of Fialuridine administration, seven other patients showed signs of severe hepatic toxicity five of which could not survive and other two could survive only after liver transplantation.[17]”
From TGN1412: From Discovery to Disaster (2010) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wong, D., Cheung, A. M., O'Rourke, K., Naylor, C. D., Detsky, A. S., & Heathcote, J. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-4-199308150-00011 · Cited by 974
Perrillo, R. P., Schiff, E. R., Davis, G. L., Bodenheimer, H. C., Lindsay, K. L., Payne, J., Dienstag, J. L., O'Brien, C., Tamburro, C. H., Jacobson, I. M., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008023230503 · Cited by 838
Mitochondrial Myopathy Caused by Long-Term Zidovudine Therapy
Dalakas, M. C., Illa, I., Pezeshkpour, G. H., Laukaitis, J. P., Cohen, B. H., & Griffin, J. L. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004193221602 · Cited by 837
Doong, S.-L., Tsai, C. H., Schinazi, R. F., Liotta, D. C., & Cheng, Y. C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8495 · Cited by 513
Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy
Arnaudo, E., Shanske, S., DiMauro, S., Schon, E. A., Moraes, C. T., Schon, E. A., & Dalakas, M. C. (1991) · The Lancet · doi:10.1016/0140-6736(91)91294-5 · Cited by 504
Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B
Hoofnagle, J. H., Peters, M. G., Mullen, K. D., Jones, D. B., Rustgi, V. K., Bisceglie, A. M. D., Hallahan, C. W., Park, Y., Meschievitz, C., & Jones, E. A. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90367-8 · Cited by 420
Self-citationReversal of Fulminant Hepatic Failure Using An Extracorporeal Liver Assist Device
Sussman, N., Chong, M. G., Koussayer, T., He, D.-E., Shang, T. A., Whisennand, H. H., & Kelly, J. H. (1992) · Hepatology · doi:10.1002/hep.1840160112 · Cited by 341
Chen, C., Vazquez-Padua, M. A., & Cheng, Y. C. (1991) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)11067-5 · Cited by 296
A controlled trial of interferon with or without prednisone priming for chronic hepatitis B
Lok, A. S.-F., Wu, P., Lai, C., Lau, J. Y. N., Leung, E. K. Y., Wong, L. S. K., Ma, O. C. K., Lauder, I. J., Ng, C. P. L., & Chung, H.-T. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90337-x · Cited by 239
Hodge, R. A. V., Sutton, D., Boyd, M. R., Harnden, M. R., & Jarvest, R. L. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.10.1765 · Cited by 207
Lewis, W., Gonzalez, B. I., Chomyn, A., & Papoian, T. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115722 · Cited by 204
Korba, B. E., & Gerin, J. L. (1992) · Antiviral Research · doi:10.1016/0166-3542(92)90056-b · Cited by 190
Fulminant Hepatic Failure Associated with 2′,3′-Dideoxyinosine (ddI)
Lai, K. K., Gang, D. L., Zawacki, J. K., & Cooley, T. P. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-4-283 · Cited by 155
Hepatomegaly with severe steatosis in HIV-seropositive patients
Freiman, J. P., Helfert, K. E., Hamrell, M. R., & Stein, D. S. (1993) · AIDS · doi:10.1097/00002030-199303000-00012 · Cited by 151
Hodge, R. A. V., & Perkins, R. M. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.2.223 · Cited by 139
Fulminant hepatitis with severe lactate acidosis in HIV‐infected patients on didanosine therapy
Bissuel, F., Bruneel, F., Habersetzer, F., CHASSARD, D., Cotte, L., Chevallier, M., Bernuau, J., Lucet, J. C., & TREPO, C. G. (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb01088.x · Cited by 135
Lactic Acidosis Complicating the Acquired Immunodeficiency Syndrome
Chattha, G. K., Arieff, A. I., Cummings, C., & Lawrence M. Tierney, Jr. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-1-199301010-00007 · Cited by 135
Cui, L., Yoon, S.-S., Schinazi, R. F., & Sommadossi, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117698 · Cited by 120
Scullard, G. H., Andres, L. L., Greenberg, H. B., Smith, J. L., Sawhney, V. K., Neal, A. E., Mahal, A. S., Pópper, H., Merigan, T. C., Robinson, W. S., et al. (1981) · Hepatology · doi:10.1002/hep.1840010306 · Cited by 96
Chen, C. H., & Cheng, Y. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50661-5 · Cited by 89
García, G., SMITH, C. I., WEISSBERG, J. I., EISENBERG, M., BISSETT, J., Nair, P. V., Mastre, B., Rosno, S., ROSKAMP, D., WATERMAN, K., et al. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-278 · Cited by 86
Kuhns, M. C., McNamara, A. L., Perrillo, R. P., Cabal, C. M., & Campbell, C. R. (1989) · Journal of Medical Virology · doi:10.1002/jmv.1890270404 · Cited by 77
Cj, M., Sm, G., & Jl, T. (1992) · PubMed · Cited by 75
Review of the Fialuridine (FIAU) Clinical Trials
Institute of Medicine (1995) · National Academies Press eBooks · doi:10.17226/4887 · Cited by 63
Controlled clinical trial of acyclovir in chronic hepatitis B virus infection
Alexander, G., Fagan, E., Hegarty, J. E., Eddleston, A. L. W. F., Williams, R. L., & Yeo, J. (1987) · Journal of Medical Virology · doi:10.1002/jmv.1890210111 · Cited by 59
Fialuridine accumulates in DNA of dogs, monkeys, and rats following long-term oral administration
Richardson, F. C., Engelhardt, J. A., & Bowsher, R. R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.25.12003 · Cited by 58
Gopinath, R., Hutcheon, M., Cheema‐Dhadli, S., & Halperin, M. L. (1992) · Journal of the American Society of Nephrology · doi:10.1681/asn.v361212 · Cited by 51
Lewis, L. D., Hamzeh, F. M., & Lietman, P. S. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.9.2061 · Cited by 44
Therapy of chronic hepatitis B with a 6-month course of ribavirin
Fried, M. W., Fong, T., Swain, M. G., Park, Y., Mp, B., Banks, S. M., Hoofnagle, J. H., & Bisceglie, A. M. D. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80387-3 · Cited by 42
Self-citationFourel, I., Li, J. C., Hantz, O., Jacquet, C., Fox, J. J., & TREPO, C. G. (1992) · Journal of Medical Virology · doi:10.1002/jmv.1890370209 · Cited by 41
A Pilot Study of 2′,3′–Dideoxyinosine for the Treatment of Chronic Hepatitis B
Fried, M. W., Korenman, J. C., Bisceglie, A. M. D., Park, Y., Waggoner, J. G., Mitsuya, H., Hartman, N. R., Yarchoan, R., Broder, S. E., & Hoofnagle, J. H. (1992) · Hepatology · doi:10.1002/hep.1840160402 · Cited by 39
Self-citationKlecker, R. W., Katki, A. G., & Collins, J. M. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09870-0 · Cited by 39
Janssen, H. L. A., Berk, L., Heijtink, R. A., ten Kate, F. J. W., & Schalm, S. W. (1993) · Hepatology · doi:10.1002/hep.1840170306 · Cited by 34
Staschke, K. A., & Colacino, J. M. (1994) · Journal of Virology · doi:10.1128/jvi.68.12.8265-8269.1994 · Cited by 32
Colacino, J. M., Malcolm, S. K., & Jaskunas, S. R. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.9.1997 · Cited by 32
Gradon, J. D., Chapnick, E. K., & Sepkowitz, D. V. (1992) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1992.tb00542.x · Cited by 25
Clinical use of thymidine as a rescue agent from methotrexate toxicity
Grem, J. L., King, S. A., Sorensen, J. M., & Christian, M. C. (1991) · Investigational New Drugs · doi:10.1007/bf00176985 · Cited by 23
Review of the Fialuridine (FIAU) clinical trials
Manning, F. J., & Swartz, M. N. (1995) · Cited by 3
Research works printed but not linked: 7
- Dusheiko G, Hoofnagle JH. Hepatitis B. In: McIntyre N, Benhamou JP, Bircher J, Rizzetto M, Rodes J, eds. Oxford textbook of clinical hepatology. New York: Oxford University Press, 1991:571-92.
- Paar DP, Hooten TM, Smiles KA, et al. The effect of FIAU on chronic hepatitis B virus (HBV) infection in HIV-infected subjects (ACTG 122b). In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, Calif., October 10–14, 1992. Washington, D.C.: American Society for Microbiology, 1992:264. abstract.
- 10.1002/hep.1840160402 · DOI
- Stevenson W, 1995, Transplant Proc, 27, 1219
- Chen CH, 1991, Mol Pharmacol, 39, 625
- Klecker RW, 1994, Mol Pharmacol, 46, 1204
- Maxson CJ, 1992, Am J Gastroenterol, 87, 708
Cited by
Sorted by citations
Lee, W. M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712113372406 · Cited by 2,559
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Adverse effects of antiretroviral therapy
Carr, A. D., & Cooper, D. A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02854-3 · Cited by 1,076
Metadata
- Authors
- McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., Luciano, C., Pruett, T., Stotka, J. L., Straus, S. E., & Hoofnagle, J. H.
- Affiliations
- National Institutes of Health (US)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
- National Institute of Allergy and Infectious Diseases (US)
- National Cancer Institute (UA)
- University of Virginia Hospital (US)
- Eli Lilly (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1995-10-26
- Volume
- 333
- Issue
- 17
- Pages
- 1099-1105
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2327070670
- Cited by
- 616
- References
- 39
- Citations by year
- 2026: 14 · 2025: 11 · 2024: 17 · 2023: 13 · 2022: 11 · 2021: 19 · 2020: 13 · 2019: 26 · 2018: 32 · 2017: 23 · 2016: 27 · 2015: 16 · 2014: 12 · 2013: 16 · 2012: 10
- FWCI
- 28.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- NIH Clinical Center
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Keywords
- FIAU, lactic acidosis, liver failure, hepatotoxicity, chronic hepatitis B, nucleoside analogues, drug toxicity, mitochondrial damage, pancreatitis, neuropathy, myopathy, liver transplantation, drug-induced liver injury
- MeSH terms
- Acidosis, Lactic, Adult, Alanine Transaminase, Antiviral Agents, Arabinofuranosyluracil, Chronic Disease, DNA, Mitochondrial, DNA, Viral, Female, Hepatitis B, Humans, Jaundice, Liver, Male, Middle Aged, Pancreatitis, Peripheral Nervous System Diseases, Drugs, Investigational, Liver Transplantation, Liver Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
